Lumbar Degenerative Disc Disease Market Size 2032: Drugs, Clinical Trials, FDA Approval and Companies by DelveInsight | Spine BioPharma, MCRA, Synthes USA HQ, NuVasive, Globus Medical Inc, Spineology

Lumbar Degenerative Disc Disease Market Size 2032: Drugs, Clinical Trials, FDA Approval and Companies by DelveInsight | Spine BioPharma, MCRA, Synthes USA HQ, NuVasive, Globus Medical Inc, Spineology
Lumbar Degenerative Disc Disease Market
Some of the key companies working in the Lumbar Degenerative Disc Disease Market are Spine BioPharma, MCRA, Synthes USA HQ, NuVasive, Globus Medical Inc, Spineology Inc, Ranier Technology Limited, DiscGenics, Invibio, Yuhan Corporation, Orthofix, Janssen Korea, Eisai, Angitia Biopharmaceuticals, Baxter Healthcare Corporation, Apatech, Zimmer Biomet

“The Lumbar Degenerative Disc Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Lumbar Degenerative Disc Disease pipeline products will significantly revolutionize the Lumbar Degenerative Disc Disease market dynamics”

 

The Lumbar Degenerative Disc Disease market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Lumbar Degenerative Disc Disease market size from 2019 to 2032. The report also covers current Lumbar Degenerative Disc Disease treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

 

Key Takeaways from the Lumbar Degenerative Disc Disease Market Report

  • The increase in Lumbar Degenerative Disc Disease market size is a direct consequence of the increasing prevalent population of lumbar degenerative disc disease patients in the 7MM.
  • The leading Lumbar Degenerative Disc Disease Companies working in the market include Spine BioPharma Inc, MCRA, Synthes USA HQ Inc, NuVasive, Globus Medical Inc, Spineology Inc, Ranier Technology Limited, DiscGenics Inc, Invibio Ltd, Yuhan Corporation, Orthofix Inc., Janssen Korea, Ltd, Eisai Inc, Angitia Biopharmaceuticals, DiscGenics Inc, Baxter Healthcare Corporation, Apatech Inc, Zimmer Biomet, and others
  • Promising Lumbar Degenerative Disc Disease Pipeline Therapies in the various stages of development include YH14618, Intradiscal rhGDF-5, AGA111, Sodium Hyaluronate, ALLOB® cells with ceramic scaffold, AMG0103, Tylenol, MPC-06-ID, and others.
  • On June 2023, Spine BioPharma Inc announced a study of phase 3 clinical trials for SB-01 for injection. The purpose of the study is to confirm the safety and effectiveness of SB-01. For Injection in adult patients with chronic low back pain and related disability due to Lumbar Degenerative Disc Disease. The primary effectiveness hypothesis is superiority of the investigational product relative to control in terms of the percentage of subjects improving in pain-related disability.
  • On January 2023, DiscGenics Inc announced a study of phase 1 clinical trials for IDCT, Saline Solution and Sodium Hyaluronate. The purpose of this study is to compare the safety and preliminary efficacy of intradiscal injections of two doses of IDCT (Discogenic Cells + Sodium Hyaluronate vehicle) and two controls (saline, Sodium Hyaluronate vehicle) in subjects with chronic low back pain due to Degenerative Disc Disease (DDD) at one lumbar level from L3 to S1.

 

Discover more about therapies set to grab major Lumbar Degenerative Disc Disease Market Share @ Lumbar Degenerative Disc Disease Market Size

 

Lumbar Degenerative Disc Disease Overview

Degenerative disc disease (DDD) is a condition in which a damaged spinal disc causes pain; simply put, it is caused by “wear and tear” on a spinal disc. Lumbar degenerative disc disease in the lumbar spine, or lower back, refers to a syndrome in which age-related wear and tear on a spinal disc causes low back pain.

 

Lumbar Degenerative Disc Disease Epidemiology Segmentation in the 7MM

  • Total Lumbar Degenerative Disc Disease Prevalent Cases
  • Lumbar Degenerative Disc Disease Diagnosed Prevalent Cases
  • Lumbar Degenerative Disc Disease Age-Specific Cases

 

Download the report to understand which factors are driving Lumbar Degenerative Disc Disease Epidemiology Trends @ Lumbar Degenerative Disc Disease Epidemiological Insights

 

Lumbar Degenerative Disc Disease Market Insights

The majority of the patients with lumbar Degenerative Disc Disease improve without surgical treatment. A course of at least6 weeks of physical therapy with an emphasis on core strengthening and stretching should be attempted. Nonsurgical interventions include cognitive therapy, lifestyle modification, and modification of the activity that may exacerbate the pain, NSAIDs, and epidural injections.

 

Lumbar Degenerative Disc Disease Market Landscape

The ultimate goal of management of lumbar Degenerative Disc Disease is to maintain the balance between synthesis and degradation of the ECM and subsequent disc hydration despite all of the degenerative factors involved, with the belief that maintenance or restoration of disc health accompanied by symptom reduction and prolonged function of the lumbar motion segment.

 

To know more about Lumbar Degenerative Disc Disease Treatment options, visit @ Lumbar Degenerative Disc Disease Drugs

 

Lumbar Degenerative Disc Disease Market Dynamics

The overall lumbar degenerative disc disease market dynamics are not robust but are anticipated to change in the coming years due to the expected launch of emerging therapies like MPC-06-ID, BRTX-100, and others.

 

Scope of the Lumbar Degenerative Disc Disease Market Report

  • Coverage- 7MM
  • Lumbar Degenerative Disc Disease Companies- Spine BioPharma Inc, MCRA, Synthes USA HQ Inc, NuVasive, Globus Medical Inc (NYSE: GMED), Spineology Inc, Ranier Technology Limited, DiscGenics Inc, Invibio Ltd, Yuhan Corporation, Orthofix Inc (NYSE:  OFIX)., Janssen Korea, Ltd, Eisai Inc (NYSE: ESALF), Angitia Biopharmaceuticals, DiscGenics Inc, Baxter Healthcare Corporation (NYSE: BAX), Apatech Inc, Zimmer Biomet (NYSE: ZBH), and others
  • Lumbar Degenerative Disc Disease Pipeline Therapies- YH14618, Intradiscal rhGDF-5, AGA111, Sodium Hyaluronate, ALLOB® cells with ceramic scaffold, AMG0103, Tylenol, MPC-06-ID, and others
  • Lumbar Degenerative Disc Disease Segmentation: Product Type, Molecule Type, Route of Administration

 

Learn more about the Lumbar Degenerative Disc Disease Pipeline Therapies in clinical trials @ Lumbar Degenerative Disc Disease Market Landscape

 

Table of Content

  1. Key Insights
  2. Executive Summary of Lumbar Degenerative Disc Disease (DDD)
  3. Competitive Intelligence Analysis for Lumbar Degenerative Disc Disease (DDD)
  4. Lumbar Degenerative Disc Disease (DDD): Market Overview at a Glance
  5. Lumbar Degenerative Disc Disease (DDD): Disease Background and Overview
  6. Patient Journey
  7. Lumbar Degenerative Disc Disease (DDD) Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Lumbar Degenerative Disc Disease Unmet Needs
  10. Key Endpoints of Lumbar Degenerative Disc Disease (DDD) Treatment
  11. Lumbar Degenerative Disc Disease Marketed Products
  12. Lumbar Degenerative Disc Disease Emerging Therapies
  13. Lumbar Degenerative Disc Disease (DDD): Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Lumbar Degenerative Disc Disease Market Outlook
  16. Access and Reimbursement Overview of Lumbar Degenerative Disc Disease (DDD)
  17. KOL Views
  18. Lumbar Degenerative Disc Disease Market Drivers
  19. Lumbar Degenerative Disc Disease Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

 

Get in touch with our Business executive @ Lumbar Degenerative Disc Disease Market Drivers and Barriers

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services


Posted

in

by

Tags: